Patient No. | Age yrs | Sex | Height cm | Weight kg | Mean Ppa mmHg | PVR dyn·s·cm−5 | CI L·min−1·m−2 | Pcv mmHg | Ppaw mmHg | Sv,O2 % | Pa,O2 mmHg | NYHAFC |
1 | 31 | Female | 160 | 62 | 40 | 1618 | 1.08 | 3 | 4 | 45.2 | 87 | III |
2 | 29 | Female | 168 | 43 | 49 | 2222 | 1.11 | 23 | 4 | 37.8 | 97 | IV |
3 | 41 | Female | 167 | 52 | 48 | 924 | 2.25 | 3 | 7 | 54.1 | 42 | IV |
4 | 41 | Female | 162 | 64 | 40 | 843 | 2.09 | 4 | 6 | 59.2 | 63 | III |
5 | 34 | Male | 179 | 62 | 44 | 787 | 2.40 | 4 | 2 | 51.3 | 73 | III |
6 | 51 | Male | 172 | 70 | 45 | 625 | 2.87 | 0 | 4 | 70.9 | 75 | III |
7 | 43 | Male | 176 | 73 | 39 | 472 | 3.14 | 1 | 4 | 62.4 | 66 | III |
8 | 36 | Female | 162 | 61 | 45 | 783 | 2.34 | 12 | 5 | 52.2 | 71 | III |
Ppa: pulmonary arterial pressure
PVR: pulmonary vascular resistance
CI: cardiac index
Pcv: central venous pressure
Ppaw: pulmonary arterial wedge pressure
Sv,O2: mixed venous oxygen saturation
Pa,O2: arterial oxygen tension
NYHAFC: New York Heart Association Functional Class
Patients 1–4 underwent long-term treatment with inhaled iloprost. 1 mmHg=0.133 kPa; 1 dyn·cm−2=0.1 Pa.